|Dr. Laurent Fischer||Pres, CEO & Director||921.08k||N/A||1964|
|Mr. Kishor Peter Soparkar J.D.||Chief Operating Officer||622.55k||N/A||1971|
|Dr. Brigit Riley Ph.D.||Chief Scientific Officer||816.08k||N/A||1978|
|Mr. John W. Rakow J.D.||Sr. VP, Gen. Counsel & Acting CFO||N/A||N/A||1957|
|Ms. Nancy E. Pecota||Principal Accounting Officer||N/A||N/A||1960|
|Mr. Heikki Jouttijarvi||Sr. VP & Head of Technical Operations||N/A||N/A||N/A|
|Ms. Dena House||Sr. VP of HR, Organizational Devel. & Learning||N/A||N/A||N/A|
|Ms. Carla Fiankan||Sr. VP of Regulatory Affairs||N/A||N/A||N/A|
|Dr. Jim Wang Ph.D.||Chief Regulatory Officer||N/A||N/A||N/A|
|Mr. Thomas Kochy||Sr. VP and Head of Global Product Strategy & Commercial||N/A||N/A||N/A|
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Adverum Biotechnologies, Inc.’s ISS governance QualityScore as of 1 June 2022 is 7. The pillar scores are Audit: 4; Board: 5; Shareholder rights: 8; Compensation: 9.